Albumin News and Research

RSS

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

China Biologic Products second-quarter revenues increase 23.3% to $40.9 million

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for its second quarter ended June 30, 2010.

16 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.

2 Aug 2010

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Malnutrition is an important factor, influencing both morbidity and recovery after surgery. The early detection of nutritional risk would allow early intervention, which may prevent later complications. A traditional nutritional assessment often includes dietary and medical evaluations to identify significant weight loss over time, significantly low or high body weight(BW), skinfold thickness, serum nutritional factor levels and functional measurements of muscle strength.

31 Jul 2010

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission.

29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

Mediomics receives additional $460,000 in STTR Phase II grant for PINCER protein assay development

Mediomics, LLC has received an additional $460,000 in a renewal of its 2nd year STTR Phase II grant (R42GM079891) from the National Institute of General Medical Sciences. Since 2007, Mediomics has received over one million dollars of STTR funding to develop its quick and sensitive homogenous PINCER™ protein assay. The major goal of the second year project is to further increase the sensitivity of the biosensor.

28 Jul 2010

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.Carbon nanoparticles activated by bursts of laser light trigger the tiny blasts, which open holes in cell membranes just long enough to admit therapeutic agents contained in the surrounding fluid. By adjusting laser exposure, the researchers administered a small-molecule marker compound to 90 percent of targeted cells - while keeping more than 90 percent of the cells alive.

28 Jul 2010

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

Baxter second-quarter global sales increase 2% to $3.2 billion

Baxter International Inc. today announced its financial results for the second quarter of 2010, reporting earnings in line with the company's previously issued guidance of $0.90 to $0.93 per diluted share.

From Baxter International Inc. 22 Jul 2010

LBL signs strategic partnership agreement with Proliant

Lampire Biological Laboratories announced today that it signed an agreement with Proliant Health and Biologicals, manufacturer of the worlds most trusted, high quality Bovine Serum Albumin, to do contract filling & provide BSA to customers requiring less than Proliant's standard 10 kilogram packaging. Lampire will also offer made-to-order aqueous blends in buffers and package sizes to customer specifications.

22 Jul 2010

Proteinuria screening identifies risk for kidney disease progression

A morning urine test is superior to all other tests for detecting declining kidney performance in patients with diabetic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that clinicians should monitor kidney function by measuring the albumin:creatinine ratio from a first morning urine sample.

16 Jul 2010

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Biogen Idec and Swedish Orphan Biovitrum today announced that they plan to advance the companies' long-lasting, fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) into a registrational clinical trial in people with hemophilia A. The decision to advance the program is based on promising data from a Phase 1/2a open-label, cross-over, multi-center, dose-escalation study that evaluated the safety and pharmacokinetics of an intravenous injection of rFVIIIFc in 16 previously-treated patients with severe hemophilia A.

12 Jul 2010

Insights into complex interrelationships between heart and kidneys

Research is yielding new understanding of the interactions between the heart and the kidneys—particularly the cardiorenal syndrome, in which failure of either organ can lead to failure of the other. Recent insights into the complex interrelationships between the heart and kidneys are presented in a special symposium section of the July issue of The American Journal of Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation.

7 Jul 2010

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.

30 Jun 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

Early stages of kidney disease in type 1 diabetes can lead to increased risk of death, study author says

People with type 1 diabetes who have early and asymptomatic kidney damage, as indicated by small amounts of protein in the urine, are six times more likely to die compared to the general population, say researchers at the University of Pittsburgh Graduate School of Public Health. Their study, being presented at the 70th Scientific Sessions of the American Diabetes Association, also found that when kidneys remained normal over time, people with type 1 diabetes had no greater risk of death than their healthy counterparts.

28 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

MP Biomedicals to acquire ICPbio International

MP Biomedicals LLC announced today that it has signed a definitive agreement to acquire the assets of ICPbio International LTD., an Auckland, New Zealand based protein biologics manufacturing company, subject to normal closing adjustments. This acquisition places MP Biomedicals in a strong position to pursue sales and distribution of serum protein products used in research and manufacturing in the Biopharmaceutical, In vitro diagnostic and Biotech sectors.

From MP Biomedicals, LLC 14 Jun 2010